SCHEMBL10049271

SCHEMBL10049271

CC(=O)[C@@H]1CSC(C)N1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19369772 1.00 — —
SCHEMBL24161976 1.00 — —
SCHEMBL10073516 0.78 — —
SCHEMBL24378363 0.77 SMN1; SMN2 (0.37) —
SCHEMBL8278626 0.70 CHRM2 (0.35) —
SCHEMBL8278625 0.69 CHRNB2 (0.31) —
SCHEMBL14887316 0.66 — —
SCHEMBL14868203 0.65 SMN1; SMN2 (0.34) —
SCHEMBL14597372 0.64 — —
SCHEMBL18069335 0.64 PHGDH (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140162943-A1 N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS ASTRAZENECA PHARMACEUTICALS, LP (US) 2014-06-12 — — US disclosed
US-20140162943-A1 N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS ASTRAZENECA PHARMACEUTICALS, LP (US) 2014-06-12 — — US disclosed
US-8642544-B2 N-terminus conformationally constrained GLP-1 receptor agonist compounds AMYLIN PHARMACEUTICALS, LLC (US) 2014-02-04 — — US disclosed
US-20120046222-A1 N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS AMYLIN PHARMACEUTICALS, INC. (US) 2012-02-23 — — US disclosed
US-20120046222-A1 N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS AMYLIN PHARMACEUTICALS, INC. (US) 2012-02-23 — — US disclosed
WO-2010120476-A2 N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS AMYLIN PHARMACEUTICALS, INC. (US) 2010-10-21 — — WO disclosed
Send feedback